Bio-Tissue, Inc. was founded in 1997 due to an unmet need for a better surgical and therapeutic alternative for ocular surface conditions; one that would serve as a non-immunogenic tissue replacement and would facilitate tissue regeneration. Initial research began in the 1980’s, led by Scheffer C.G. Tseng, MD, PhD, who believed the solution was to utilize the natural properties of human amniotic membrane tissue to promote wound healing. In the late 1990’s, Dr. Tseng introduced the use of amniotic membrane for ocular surface reconstruction, by utilizing a novel method of processing and preservation – the CryoTek® Method. Today, the company’s regenerative wound healing solutions are used by eye care professionals around the world.
Bio-Tissue, Inc., a subsidiary of TissueTech, Inc., is a privately held ophthalmic biologic therapeutics company that develops innovative wound care and ocular hygiene solutions for the prevention and treatment of ocular surface diseases and disorders. Bio-Tissue provides a comprehensive line of cryopreserved amniotic membrane products, including AmnioGraft, a biologic ocular transplantation graft; AmnioGuard, a biologic glaucoma shunt tube graft; and PROKERA® family of biologic corneal bandage devices.
These products incorporate human amniotic membrane processed with the Company’s proprietary CryoTek method that ensures the tissue retains its full biologic activity to reduce inflammation, promote healing, minimize corneal scarring, and inhibit the angiogenic process.
Bio-Tissue also develops and markets Cliradex®, a natural lid, lash and facial cleanser with 4-Terpineol, the most important component of tea tree oil (TTO), for the management of symptoms of lid margin diseases such as blepharitis, demodex, and rosacea.
Bio-Tissue is a leader in the ophthalmic industry with over 15 years of clinical history, 25 years of government-funded scientific research, 300 peer-reviewed publications, and over 175,000 successful human transplantations.